12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Tuesday's pre-market session, several healthcare stocks showed significant movement. BioCardia (BCDA) saw a substantial increase of 115.5% to $0.86, while BioXcel Therapeutics (BTAI) experienced a sharp decline of 37.9% to $3.42. Other notable gainers included Theseus Pharmaceuticals (THRX), INVO Bioscience (INVO), Genfit (GNFT), Redhill Biopharma (RDHL), and Biodexa Pharmaceuticals (BDRX). On the losing side, Harrow (HROW), Tenax Therapeutics (TENX), Akili (AKLI), Renalytix (RNLX), and TRACON Pharma (TCON) saw their stock prices fall. The movements were largely attributed to recent earnings reports.
November 14, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCardia's stock surged by 115.5% to $0.86 in the pre-market session following their Q3 earnings report released 4 days ago.
The significant surge in BioCardia's stock price is likely due to a positive reception of their Q3 earnings report. Such a large increase suggests strong investor confidence and could lead to continued short-term upward momentum.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Biodexa Pharmaceuticals' stock increased by 12.76% to $2.65, with a market value of $1.8 million.
Biodexa Pharmaceuticals' stock rise suggests investor interest which may continue to drive the stock upward in the short term.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Genfit's stock increased by 13.84% to $3.7, with a market value of $184.3 million.
Genfit's stock rise could be influenced by market sentiment or specific company news. The increase may lead to short-term positive momentum.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
INVO Bioscience's stock rose by 33.54% to $2.15 following their Q3 earnings report released yesterday.
The increase in INVO Bioscience's stock price is likely due to a positive investor reaction to their Q3 earnings report. This could suggest a short-term positive trend for the stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Redhill Biopharma's stock rose by 13.41% to $0.35, with a market value of $3.8 million.
The increase in Redhill Biopharma's stock price may be due to investor optimism or recent positive developments. This could lead to short-term upward movement in the stock.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Theseus Pharmaceuticals' stock increased by 34.57% to $2.88, with a market cap of $125.5 million.
Theseus Pharmaceuticals' stock rise could be attributed to market dynamics or recent company developments. The substantial increase may attract more investor interest in the short term.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Akili's shares fell by 19.25% to $0.36 following their Q3 earnings report released 3 days ago.
Akili's stock price drop is likely due to a negative investor reaction to their Q3 earnings report, suggesting possible continued bearish sentiment in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
BioXcel Therapeutics' shares fell by 37.9% to $3.42 during the pre-market session after the release of their Q3 earnings today.
BioXcel Therapeutics' significant stock price drop is likely a direct reaction to their Q3 earnings report. The magnitude of the decline indicates a negative investor response, which could lead to further short-term bearish behavior.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Harrow's shares decreased by 24.79% to $9.65 after their Q3 earnings report released yesterday.
Harrow's stock price drop is likely a reaction to their Q3 earnings report, indicating a negative investor response that could persist in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Renalytix's stock decreased by 14.45% to $0.73 after their Q1 earnings report released today.
The decrease in Renalytix's stock price is a direct response to their Q1 earnings report, indicating a negative investor sentiment that may influence short-term price action.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
TRACON Pharma's stock fell by 13.56% to $0.18 following their Q3 earnings report released 3 days ago.
TRACON Pharma's stock decline is likely due to investor dissatisfaction with their Q3 earnings report, which could lead to further short-term negative price movement.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Tenax Therapeutics' shares fell by 22.59% to $0.48, with a market cap of $11.4 million.
The decline in Tenax Therapeutics' stock price could reflect investor concerns or a negative market reaction to recent news, potentially leading to further short-term downside.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 80